Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Core Insights - Zentalis Pharmaceuticals is advancing the late-stage development of its first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment for ovarian cancer [1][3] - The management team will participate in a fireside discussion at Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11 in New York [1] Company Overview - Zentalis Pharmaceuticals focuses on developing innovative oncology treatments, particularly for ovarian cancer and various tumor types [3] - The company aims to provide a targeted, non-chemotherapy, orally available medicine that enhances treatment experience and outcomes for cancer patients [3] Event Information - A live webcast of the upcoming event will be available for at least 30 days after the event concludes, accessible under the "Events & Presentations" tab on the company's website [2]